These findings indicate that Bmi‐1 could promote angiogenesis in glioma via NF‐κB/VEGF‐C, further suggesting that NF‐κB/VEGF‐C‐dependent Bmi‐1 may represent a novel therapeutic target for antiangiogenic strategies aimed at glioma. Here, NFKB1 is linked to glioma.